---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-22-001136"
form_type: "8-K"
ticker: "CDIO"
cik: "0001870144"
company_name: "Cardio Diagnostics Holdings, Inc."
filed_at: "2022-09-21T23:59:59+00:00"
generated_at: "2026-06-23T08:22:23.536701+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardio Diagnostics secures U.S. patent for cardiovascular disease detection technology

## Summary
- U.S. Patent No. 11,414,704 issued by USPTO to University of Iowa Research Foundation (UIRF), exclusively licensed to Cardio Diagnostics.
- Patent covers compositions and methods for detecting predisposition to cardiovascular disease; co-invented by Cardio founders/CEO Meesha Dogan and CMO Robert Philibert.
- The patent technology is used in Cardio's flagship product Epi+Gen CHD, a three-year symptomatic CHD risk assessment test introduced in 2021.
- Cardio Diagnostics is merging with Mana Capital Acquisition Corp. (Nasdaq: MAAQU) in a previously announced business combination.

## SEC filing metadata
- accession: 0001079973-22-001136
- form_type: 8-K
- ticker: CDIO
- cik: 0001870144
- company_name: Cardio Diagnostics Holdings, Inc.
- filed_at: 2022-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870144/000107997322001136/0001079973-22-001136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870144/000107997322001136/mana_8k-092022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-22-001136
- JSON: https://secwatch.observer/filing/0001079973-22-001136.json
- Plain text: https://secwatch.observer/filing/0001079973-22-001136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.